Understanding the variability in Parkinson's -- across causes, symptoms and progression -- can help us develop and test more targeted therapies.
"Why after 20 years with Parkinson's disease is one person doing crosswords and another person is experiencing dementia five years after diagnosis?" said Bastiaan Bloem, MD, PhD, professor of Neurological Movement Disorders at Radboud University Nijmegen Medical Centre in the Netherlands and founder of ParkinsonNet.
Radboud University; ParkinsonNet, a network of Parkinson's care providers; and research organization Verily Life Sciences today announced a longitudinal study in the Netherlands to better understand Parkinson's variability and support development of personalized treatments.
The study is modeled after the MJFF-led Parkinson's Progression Markers Initiative and will, like PPMI, make its data accessible to the broad research community.
"We know that findings from any study gain value if they can be replicated and found consistent across different populations," said MJFF CEO Todd Sherer, PhD. "Having two studies modeled in a similar fashion dramatically accelerates the speed we can validate and actionize insights."
Read a press release to learn more about the new study.
PPMI is recruiting people with a genetic link to Parkinson's disease. Take a short survey to learn if you may be eligible.